The Neurology Minute® podcast delivers a brief daily summary of what you need to know in the field of neurology, the latest science focused on the brain, and timely topics explored by leading neurologists and neuroscientists. From the American Academy of Neurology and hosted by Stacey Clardy, MD, PhD, FAAN, with contributions by experts from the Neurology® journals, Neurology Today®, Continuum®, and more.
Reduced activity in multiple sclerosis can be more than a diary observation. This short critical appraisal item links repeated wrist-worn accelerometer changes with later disability worsening and deep grey matter or thalamic volume loss, while keeping causation off the claim.
POLG-related mitochondrial disease is a specialist neurology choice. It keeps testing tied to phenotype clarity: targeted genetics for defined patterns, broader sequencing for complex presentations, GDF15 as supportive evidence and muscle biopsy when adult or inconclusive cases still need clarification.
Protected lactation breaks are a rota issue, not a favour. The short neurology item is for supervisors planning return to work, where 30-minute breaks every two to three hours, suitable space and milk storage need to be agreed before clinic templates go live.
The neurology meeting update is short and least bedside-facing, but it gives a clear professional-learning task: turn research investment, workforce development and interdisciplinary collaboration into something shared locally, especially when live attendance is not possible.
Ptosis, ophthalmoplegia, unsteady gait, limb weakness and peripheral nerve symptoms make this a short but specialist neurology choice. Choose it for revision or clinic work where mitochondrial disease, POLG-related disease, polyneuropathy and myopathy need to stay connected despite an incomplete early picture.
Milk expression at work is physiology, not a favour squeezed between clinics. Protected 20–30 minute breaks every 2–3 hours, room access and rota planning reduce risks to supply and complications from insufficient expression.
EBV antibody work is mainly for neuroinflammatory diagnostic discussion. A single high result is not enough; persistent high responses over time may support MS differentiation from MOGAD or NMOSD when the clinical picture fits.
A stroke-code patient with recurrent transient deficit and new multifocal intracranial stenosis is not a routine pathway case. Open this first: link symptoms, vascular imaging, blood work and biopsy before deciding whether vasculitis, reversible cerebral vasoconstriction syndrome or refractory cerebrovascular events need escalation.
EBV serology can support neuroinflammatory reasoning, but the association with multiple sclerosis is not a complete causal story. Keep antibody results beside the clinical history, examination and established work-up rather than turning exposure into diagnosis.
MOGAD maintenance treatment is specialist, but the timing lesson is concrete. Early oral corticosteroids can reduce relapse risk, with the spreadsheet naming about 12.5 mg/day and a five-month practical target after a first attack before benefit attenuates.
.svg)